# GOVX catalysts: GeoVax Labs, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/govx/catalysts

> GeoVax Labs, Inc. (GOVX) has 2 upcoming catalysts. The next is the covid-19 vaccine topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GeoVax Labs, Inc. |
| Ticker | GOVX (Nasdaq) |
| SEC CIK | 832489 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/govx |

## Cash runway

Cash $2.2M as of 2026-09-30; quarterly burn $4.3M; about 1.5 months of runway at that rate (XBRL company facts, accession 0001437749-26-036546).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2024 | [GeoVax Labs, Inc. interim data readout](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | scheduled | "Existing Phase 2 clinical studies: During the fourth quarter of 2024, GeoVax anticipates reporting interim results from (a) the comparative trial among Immunocompromised/Chronic Lymphocytic Leukemia (CLL) patients and (b) the booster trial among healthy adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/ex_747310.htm)) |
| November 12, 2024 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774924034910/ex_747310.htm)) |
| March 27, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports 2024 Year-End Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925009859/ex_795727.htm)) |
| Q2 2025 | [GeoVax Labs, Inc. topline data readout](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | scheduled | "Healthy Adult Booster Trial - Enrollment is complete, with data readout expected in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm)) |
| May 1, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925014147/ex_809992.htm)) |
| July 28, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/ex_843599.htm)) |
| November 13, 2025 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925034903/ex_887958.htm)) |
| April 15, 2026 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports 2025 Year-End Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/ex_945907.htm)) |
| May 14, 2026 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports First Quarter 2026 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/ex_962125.htm)) |
| 2H 2026 | [Fludarabine trial start](https://sec-api.dev/pdufa/fludarabine) | GOVX |  | scheduled | "GeoVax expects to initiate its Phase 3 trial in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/ex_843599.htm)) |
| July 27, 2026 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/ex_993355.htm)) |
| Dec 2026 to Mar 2027 | [Covid-19 vaccine topline data readout](https://sec-api.dev/pdufa/covid-19-vaccine) | GOVX | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia | scheduled | "NCT04977024 (SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor GeoVax, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04977024)) |
| December 2026 | [Covid-19 vaccine primary completion](https://sec-api.dev/pdufa/covid-19-vaccine) | GOVX | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia | scheduled | "NCT04977024 (SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor GeoVax, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04977024)) |

## Drugs

- [Covid-19 vaccine](https://sec-api.dev/pdufa/covid-19-vaccine): COVID-19 Infection

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/govx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GOVX catalysts: GeoVax Labs, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/govx/catalysts

```bibtex
@misc{secapidev_companies_govx_catalysts_20261116,
  title        = {GOVX catalysts: GeoVax Labs, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/govx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_govx_catalysts_20261116","title":"GOVX catalysts: GeoVax Labs, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/govx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
